58 / 86
58
Efficacy data: licensed indication
Parameter
Eribulin*
¥
Trabectedin
¥
Pazopanib
†
OS
15,6m vs 8,4m
13,7 vs 13,1m
12,5m vs 10,7m
HR=0.511 (0.346–
0.753)
HR=0,927 (0,748-
1,150)
HR=0,86 (0,67-1,11)
PFS
2,9m vs 1,7m
4,2m vs 1,5m
4,6m vs 1,6m
HR=0,52 (0,346-
0,784)
HR=0,55 (0,436-
0,696)
HR=0,31 (0,24-0,40)
ORR
4% vs 5%
p:=0,62
9,9% vs 6,9%
P=0,32
6% vs 0%
P=?
TTR (median)
3,2m vs 2,8m
‡
NA
NA
DOR (median)
12,5m vs 4,2
‡
6,47m vs 4,17m
8,6m
# of cycles
Median: 3
‡
Median: 4
NA
Signifi
cant
No
Significant
*LPS;
¥
DTIC as comparator;
†
PCBO as comparator;
‡
Data on file